Incidence of second primary cancers in patients with retinoblastoma: a systematic review and meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hereditary retinoblastoma patients face a significantly higher risk of second primary cancers compared to nonhereditary patients. Treatments like chemotherapy and radiation increase this risk, emphasizing the need for radiation protection and tailored care.
Area Of Science
- Oncology
- Genetics
- Public Health
Background
- Retinoblastoma (Rb) survivors, particularly those with hereditary forms, may have an increased risk of developing second primary cancers (SPCs).
- Existing evidence on the long-term risk of SPCs in Rb patients is fragmented, necessitating a comprehensive synthesis.
Approach
- A systematic review and meta-analysis was performed, searching PubMed, EMBASE, and Cochrane Library up to March 2023.
- Ten studies, including nine of high quality, were analyzed to calculate standardized incidence ratios (SIRs) for SPCs in Rb patients.
- Study quality was assessed using the Newcastle-Ottawa Scale.
Key Points
- Hereditary Rb patients exhibited a significantly elevated SIR for SPCs (17.55), while nonhereditary Rb patients showed a non-significant increase (1.36).
- Specific SPCs with notably high SIRs included nasal cavity tumors (591.06), bone tumors (442.91), and soft tissue sarcomas (202.93).
- Chemotherapy and radiation therapy were identified as factors associated with increased SPC risk in hereditary Rb patients.
Conclusions
- Hereditary Rb patients have a substantially higher risk of developing second primary cancers.
- The type of second primary cancer and specific treatments like chemotherapy and radiation influence risk.
- Enhanced radiation protection and individualized management strategies are crucial for Rb survivors.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...